NovoCure Limited (NVCR)
18.51
0.74 (4.16%)
At close: Apr 24, 2025, 3:59 PM
19.22
3.83%
After-hours: Apr 24, 2025, 07:36 PM EDT
Company Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China.
Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma.
The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.
NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
NovoCure Limited

Country | JE |
IPO Date | Oct 1, 2015 |
Industry | Medical - Instruments & Supplies |
Sector | Healthcare |
Employees | 1,488 |
CEO | William F. Doyle |
Contact Details
Address: No. 4 The Forum Saint Helier, JE | |
Website | https://www.novocure.com |
Stock Details
Ticker Symbol | NVCR |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001645113 |
CUSIP Number | G6674U108 |
ISIN Number | JE00BYSS4X48 |
Employer ID | 00-0000000 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
Barak Ben-Arye | General Counsel |
Dr. Nicolas Leupin M.B.A., M.D., Ph.D. | Chief Medical Officer |
William F. Doyle | Executive Chairman |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 23, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Apr 22, 2025 | 8-K | Current Report |
Apr 21, 2025 | DEFA14A | Filing |
Apr 21, 2025 | DEF 14A | Filing |
Apr 01, 2025 | SCHEDULE 13G | Filing |
Mar 06, 2025 | 4 | Filing |
Mar 06, 2025 | 4 | Filing |
Mar 06, 2025 | 4 | Filing |
Mar 06, 2025 | 4 | Filing |
Mar 06, 2025 | 4 | Filing |